4-氯-1H-吡咯并[2,3-b]吡啶-4-胺 | 1040683-00-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 4-氯-1H-吡咯并[2,3-b]吡啶-4-胺
• 中文别名: 5-氯-1H-吡咯并[2,3-b]吡啶-4-胺
• 英文名称: 5-chloro-1H-pyrrolo[2,3-b]pyridin-4-ylamine
• 英文别名: 5-Chloro-1H-pyrrolo[2,3-b]pyridin-4-amine
• CAS: 1040683-00-8
• 化学式: C₇H₆ClN₃
• mdl: MFCD10574984
• 分子量: 167.598
• InChiKey: RTDLKNOVHGITIF-UHFFFAOYSA-N

物化性质

• 密度：
  1.533±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• WGK Germany：
  3
• 海关编码：
  2933990090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P301+P310,P305+P351+P338
• 危险品运输编号：
  2811
• 危险性描述：
  H301,H319
• 储存条件：
  储存温度应保持在2-8°C，存放时请确保容器密封并置于干燥处。

SDS

5-氯-1H-吡咯并[2,3-b]吡啶-4-胺MSDS英文版

反应信息

• 作为反应物：
  描述：

  4-氯-1H-吡咯并[2,3-b]吡啶-4-胺 、 环丙甲醛 在 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 以69%的产率得到(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)-cyclopropylmethyl-amine
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  [FR] COMPOSÉS ET MÉTHODES UTILISÉS POUR LA MODULATION DES KINASES ET INDICATIONS À CET EFFET

  摘要：

  描述了化合物及其盐、配方、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述化合物或其盐、配方、共轭物、衍生物、形式对至少一种Raf蛋白激酶具有活性。在某些方面和实施例中，所述化合物在抑制Ras突变细胞系增殖方面具有活性。还描述了使用这些方法来治疗疾病和病况，包括与B-Raf V600E突变蛋白激酶活性相关的疾病和病况，包括黑色素瘤、胶质瘤、胶质母细胞瘤、乳头状星形细胞瘤、结直肠癌、甲状腺癌、肺癌、卵巢癌、前列腺癌、肝癌、胆囊癌、胃肠间质瘤、胆道癌和胆管癌。还描述了使用这些方法来治疗与c-Raf-1蛋白激酶活性相关的疾病和病况，包括急性疼痛、慢性疼痛或多囊肾病。

  公开号：

  WO2011063159A1
• 作为产物：
  描述：

  4-氯-1-[三(甲基乙基)硅酯]-1H-吡咯并[2,3-B]吡啶 在 sodium azide 、 palladium on activated charcoal 、 仲丁基锂 、 氯化铵 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， -50.0~110.0 ℃ 、101.33 kPa 条件下， 反应 34.5h， 生成 4-氯-1H-吡咯并[2,3-b]吡啶-4-胺
  参考文献：
  名称：

  一种5-氯-1H-吡咯并[2,3-B]吡啶-4-胺的合 成方法

  摘要：

  本发明涉及一种5‑氯‑1H‑吡咯并[2,3‑B]吡啶‑4‑胺的合成方法。主要解决缺少量化合成方法的技术问题。本发明合成方法包括以下步骤：4‑氯‑7‑氮杂吲哚在四氢呋喃中和氢化钠，三异丙基氯硅烷室温下反应，生成化合物1；化合物1在四氢呋喃中和仲丁基锂，六氯乙烷低温反应，生成化合物2；化合物2和叠氮化钠，氯化铵，在N,N‑二甲基甲酰胺中高温下反应，生成化合物3；在钯碳催化作用下，化合物3在乙醇中被常压下氢化，生成目标化合物4。作为价格昂贵的精细化工产品，5‑氯‑1H‑吡咯并[2,3‑B]吡啶‑4‑胺在制药行业中得到广泛应用。

  公开号：

  CN107298679B

文献信息

• Compounds and Methods for Kinase Modulation, and Indications Therefor
  申请人：Ibrahim Prabha N.

  公开号：US20110152258A1

  公开（公告）日：2011-06-23

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

  本文描述了化合物及其盐、制剂、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述的化合物或其盐、制剂、共轭物、衍生物、形式对至少一种Raf蛋白激酶具有活性。在某些方面和实施例中，所述的化合物对抑制Ras突变细胞系的增殖具有活性。还描述了使用这些化合物的方法来治疗与B-Raf V600E突变蛋白激酶活性相关的疾病和病症，包括黑色素瘤、胶质瘤、多形性胶质母细胞瘤、毛细胞星形胶质瘤、结肠直肠癌、甲状腺癌、肺癌、卵巢癌、前列腺癌、肝癌、胆囊癌、胃肠间质瘤、胆道癌和胆管癌。还描述了使用这些化合物的方法来治疗与c-Raf-1蛋白激酶活性相关的疾病和病症，包括急性疼痛、慢性疼痛或多囊肾病。
• Compounds and methods for kinase modulation, and indications therefor
  申请人：Ibrahim Prabha N.

  公开号：US08673928B2

  公开（公告）日：2014-03-18

  and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds of Formula (I) or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

  本文描述了化合物及其盐、制剂、共轭物、衍生物、形式和用途。在某些方面和实施例中，式（I）描述的化合物或其盐、制剂、共轭物、衍生物、形式在至少一种Raf蛋白激酶上具有活性。在某些方面和实施例中，所述化合物在抑制Ras突变细胞系增殖方面具有活性。还描述了使用这些化合物的方法来治疗与B-Raf V600E突变蛋白激酶活性相关的疾病和病症，包括黑色素瘤、胶质瘤、多形性胶质母细胞瘤、乳头状星形细胞瘤、结直肠癌、甲状腺癌、肺癌、卵巢癌、前列腺癌、肝癌、胆囊癌、胃肠间质瘤、胆道肿瘤和胆管癌。还描述了使用这些化合物的方法来治疗与c-Raf-1蛋白激酶活性相关的疾病和病症，包括急性疼痛、慢性疼痛或多囊肾病。
• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Plexxikon Inc.

  公开号：US20140288070A1

  公开（公告）日：2014-09-25

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

  本文描述了化合物及其盐、制剂、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述的化合物或其盐、制剂、共轭物、衍生物、形式至少对一种Raf蛋白激酶具有活性。在某些方面和实施例中，所述的化合物具有抑制Ras突变细胞系增殖的活性。还描述了使用它们治疗疾病和病症的方法，包括与B-Raf V600E突变蛋白激酶活性相关的疾病和病症，包括黑色素瘤、胶质瘤、多形性胶质母细胞瘤、毛细胞星形细胞瘤、结直肠癌、甲状腺癌、肺癌、卵巢癌、前列腺癌、肝癌、胆囊癌、胃肠道间质瘤、胆道癌和胆管癌。还描述了使用它们治疗与c-Raf-1蛋白激酶活性相关的疾病和病症的方法，包括急性疼痛、慢性疼痛或多囊肾病。
• Pyrrolopyridines useful as inhibitors of protein kinase
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP2354139A1

  公开（公告）日：2011-08-10

  The present invention relates to compounds of formula (I) wherein Q, Z, R1, R2, and R3 are as described in claim 1 useful as inhibitors of protein kinases, particularly of JAK family and ROCK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及式(I)化合物，其中Q、Z、R1、R2和R3如权利要求1所述，可用作蛋白激酶，特别是JAK家族和ROCK家族激酶的抑制剂。本发明还提供了包含所述化合物的药学上可接受的组合物以及使用该组合物治疗各种疾病、病症或失调的方法。
• N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer
  申请人：Plexxikon Inc.

  公开号：EP2501236B1

  公开（公告）日：2017-03-29